While the potential of cell and gene therapies (CGTs) is huge, the high cost raises concerns from payers. We explore how the industry can drive the adoption of CGTs to ensure that they reach patients around the world, rather than just those in private markets

During the pandemic, low-to-middle-income countries (LMICs) have often been reliant on vaccine handouts from global initiatives and affluent nations. What are the emerging solutions that could improve access to vaccines in LMICs and self-sufficiency?

Tech giants have seized a huge share of the health and preventive technology market, but how could partnerships between the pharmaceutical and tech industries benefit patients and healthcare systems?

To be honest, my initial foray into the field of diabetes was by chance, as I took on the management of diabetes at the practice when I joined as a salaried general practitioner.

AN INTERNATIONAL COLLECTIVE of oncology clinicians and researchers came together to share the most recent updates in patient care and…

Metastatic collecting ducts carcinoma is biologically poorly characterised and under-represented in prospective randomised trials.

The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…

Opening the session, Calvo presented a compelling and balanced case about the potential that Phase 0 (Ph0) trials hold for increasing…